Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Advaxis Shares Jump After FDA Lifts Clinical Hold on Phase 1/2 Study
Advaxis Shares Jump After FDA Lifts Clinical Hold on Phase 1/2 Study
Advaxis Shares Jump After FDA Lifts Clinical Hold on Phase 1/2 Study
Submitted by
admin
on July 13, 2018 - 9:18am
Source:
CP Wire
News Tags:
Advaxis
axalimogene filolisbac
HPV head and neck cancer
cervical cancer
Headline:
Advaxis Shares Jump After FDA Lifts Clinical Hold on Phase 1/2 Study
snippet:
Shares up 38%+ in pre-market trading
Clinical Hold was issued on March 9, 2018
Axalimogene filolisbac has fast track designation for adjuvant therapy for high-risk locally advanced cervical cancer
Do Not Allow Advertisers to Use My Personal information